Sandbox Reserved 1490: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
==Crystal structure of cytoplasmic kinase domain of Tie2 in complex with decipera compound DP1919== | ==Crystal structure of cytoplasmic kinase domain of Tie2 in complex with decipera compound DP1919== | ||
<StructureSection load='6MWE' size='340' side='right' caption='Structure of the kinase domain of TIE2.' scene='' name='pp'> | <StructureSection load='6MWE' size='340' side='right' caption='Structure of the kinase domain of TIE2.' scene='' name='pp'> | ||
The protein we are focusing one is a protein kinase receptor to a family of ligands called angiopoietins. This receptor is a Tyrosine Kinase TIE2. We are going to analyze the kinase domain of this protein | The protein we are focusing one is a protein kinase receptor to a family of ligands called angiopoietins. This receptor is a Tyrosine Kinase TIE2. We are going to analyze the <scene name='80/802664/Entire_molecule/1'>kinase domain</scene> of this protein. | ||
It acts as cell-surface receptor for the ligands ANGPT1, ANGPT2 and ANGPT4 and regulates among others angiogenesis, endothelial cell survival and maintenance of vascular quiescence. It is important in the regulation of both normal physiologic and pathologic angiogenesis. The later is a fundamental step in the transition of tumors from a benign state to a malignant one. | It acts as cell-surface receptor for the ligands ANGPT1, ANGPT2 and ANGPT4 and regulates among others angiogenesis, endothelial cell survival and maintenance of vascular quiescence. It is important in the regulation of both normal physiologic and pathologic angiogenesis. The later is a fundamental step in the transition of tumors from a benign state to a malignant one. | ||